Precision Biosciences (DTIL) Liabilities from Discontinued Operations (2022 - 2025)
Precision Biosciences (DTIL) posted quarterly Liabilities from Discontinued Operations of 885000.0 for Q3 2025, down 32.13% year-over-year from 1304000.0 in Q3 2024, and little changed quarter-over-quarter from 885000.0 in Q2 2025.
Precision Biosciences (DTIL) Liabilities from Discontinued Operations (2022 - 2025) Analysis & Trends
Precision Biosciences (DTIL) has reported Liabilities from Discontinued Operations for 4 consecutive years, with 885000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Liabilities from Discontinued Operations fell 32.13% year-over-year to 885000.0; the TTM figure through Sep 2025 stood at 885000.0 (down 32.13% YoY), while the FY2024 annual figure was 1204000.0, down 52.09% from the prior year.
- Liabilities from Discontinued Operations was little changed at 885000.0 in Q3 2025 per DTIL's latest filing, from 885000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 2513000.0 in Q4 2023 and bottomed at 885000.0 in Q1 2025.
- Historically, Liabilities from Discontinued Operations has averaged 1384400.0 across 4 years, with a median of 1304000.0 in 2024.
- Annual changes were most pronounced in 2023 — Liabilities from Discontinued Operations soared 46.36% — and 2024, when it plunged 52.09%.
- Precision Biosciences' Liabilities from Discontinued Operations stood at 1717000.0 in 2022, then jumped by 46.36% to 2513000.0 in 2023, then slumped by 52.09% to 1204000.0 in 2024, then dropped by 26.5% to 885000.0 in 2025.
- Business Quant data shows DTIL's Liabilities from Discontinued Operations at 885000.0 in Q3 2025, 885000.0 in Q2 2025, and 885000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 885,000.00 |
| Sep 30, 2025 | 885,000.00 |
| Jun 30, 2025 | 885,000.00 |
| Jun 30, 2025 | 885,000.00 |
| Mar 31, 2025 | 885,000.00 |
| Mar 31, 2025 | 885,000.00 |
| Dec 31, 2024 | 1.20 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.64 Mn |
| Dec 31, 2022 | 1.72 Mn |
| Dec 31, 2022 | 1.72 Mn |